The present invention provides a method for preparing an ecteinascidin compound and an intermediate thereof, and specifically provides a preparation method for a novel compound QT9, and a method of using QT9 to prepare an ecteinascidin compound. The method provided by the present invention has high reaction selectivity and high yield, the obtained compound is easy to purify, and defects in the prior art that multiple intermediates are oily substances, and the reaction selectivity is poor are solved. The method of the present invention is particularly applicable to industrial production.

The present invention provides a method for preparing an ecteinascidin compound and an intermediate thereof, and specifically provides a preparation method for a novel compound QT9, and a method of using QT9 to prepare an ecteinascidin compound. The method provided by the present invention has high reaction selectivity and high yield, the obtained compound is easy to purify, and defects in the prior art that multiple intermediates are oily substances, and the reaction selectivity is poor are solved. The method of the present invention is particularly applicable to industrial production.

Described herein are TYK2 pseudokinase ligands and methods of utilizing TYK2 pseudokinase ligands in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.

The present invention relates to a pyrimidodiazepine derivative or a pharmaceutically acceptable salt thereof and a use thereof. A pyrimidodiazepine derivative or a pharmaceutically acceptable salt thereof according to the present invention can bind specifically to DNAJC3 and PDIA3, which are inhibitory of PERK signaling activation, to prevent the inhibition against PERK signaling. Thus, having an advantage of effectively suppressing or inhibiting tau aggregation, the pyrimidodiazepine derivative or a pharmaceutically acceptable salt thereof can not only be used in a pharmaceutical composition capable of fundamentally preventing or treating tauopathies associated with the activation of tau protein, but also can find applications in various studies on the development of therapeutic agents for tauopathies, and the expression or activity inhibition of tau protein.

Disclosed are a fused tricyclic derivative and a pharmaceutical application thereof. Specifically disclosed are a compound represented by formula (III) and a pharmaceutically acceptable salt thereof.

##STR00001##

Provided are compounds comprising a plurality of chemical groups, wherein the compound comprises a first ring, wherein the first ring is formed by connecting the plurality of chemical groups one by one with a direct bond to each other in a manner to form one or more closed rings, wherein the first ring is a ring which has a minimum number of a plurality of ring atoms in the one or more closed rings. Also provided are formulations comprising these compounds. Further provided are organic light emitting devices (OLEDs) and related consumer products that utilize these compounds.

Provided are compounds comprising a plurality of chemical groups, wherein the compound comprises a first ring, wherein the first ring is formed by connecting the plurality of chemical groups one by one with a direct bond to each other in a manner to form one or more closed rings, wherein the first ring is a ring which has a minimum number of a plurality of ring atoms in the one or more closed rings. Also provided are formulations comprising these compounds. Further provided are organic light emitting devices (OLEDs) and related consumer products that utilize these compounds.

The present disclosure relates to compounds of Formula (I′):

##STR00001##

and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for modulating orexin-2 receptor activity and may be used in the treatment of disorders in which orexin-2 receptor activity is implicated, such as narcolepsy, a hypersomnia disorder, a neurodegenerative disorder, a symptom of a rare genetic disorder, a mental health disorder, a metabolic syndrome, osteoporosis, cardiac failure, coma, or facilitating emergence from anaesthesia.

The present disclosure relates to compounds of Formula (I′):

##STR00001##

and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for modulating orexin-2 receptor activity and may be used in the treatment of disorders in which orexin-2 receptor activity is implicated, such as narcolepsy, a hypersomnia disorder, a neurodegenerative disorder, a symptom of a rare genetic disorder, a mental health disorder, a metabolic syndrome, osteoporosis, cardiac failure, coma, or facilitating emergence from anaesthesia.

The disclosure relates to USP30 Inhibitor Compounds, pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising same, and medical uses involving same.